BioWisdom Announces Second Partner of Safety Intelligence Program
News Feb 19, 2008
BioWisdom Ltd has announced a three-year agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, NV (J&JPRD).
Under the terms of the agreement, J&JPRD will become the second partner for BioWisdom’s Safety Intelligence Program (SIP). The first partnership was formed with AstraZeneca. The financial details of the deal have not been disclosed.
The Safety Intelligence Program applies BioWisdom’s Sofia technology to deliver a specialist medical search system to support drug safety risk assessment at all stages of pharmaceutical R&D. Through the partnership, J&JPRD joins BioWisdom’s SIP board.
“We are delighted to have J&JPRD join our Safety Intelligence Program and look forward to working closely with safety assessment teams across the organization and affiliates” said Dr. Julie Barnes, Chief Scientific Officer of BioWisdom. “This second partnership is a testimony to the value that the pharmaceutical industry sees in our approach to drug safety and risk management.”
Dr Jack Reynolds, Chairman of the SIP Board said, “I am delighted to see the relationship between BioWisdom and J&JPRD established. I look forward to working with all partners on the SIP Board to advance the Safety Intelligence Program for the purpose of improving our understanding of many of the major recurring and potentially serious drug-induced adverse events.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.